Keyphrases
Phase II Study
100%
CSF-1
100%
AMD3100
100%
Plerixafor
100%
Hodgkin Lymphoma
100%
Hematopoietic Stem Cell Mobilization
100%
CD34+ Cells
83%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Apheresis
33%
Historical Controls
33%
Lymphoma Patients
16%
Relapsed or Refractory
16%
Pharmacokinetics
16%
Multiple Myeloma
16%
Non-Hodgkin Lymphoma
16%
Hematopoietic Stem Cells
16%
Patient Demographics
16%
Control Population
16%
Healthy Volunteers
16%
C-X-C Chemokine Receptor Type 4 (CXCR4)
16%
Stromal Cell-derived factor-1 (SDF-1)
16%
Pharmacokinetic Analysis
16%
Relapsed Lymphoma
16%
Apheresis Procedures
16%
Refractory Hodgkin Lymphoma
16%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Plerixafor
100%
Stem Cell Mobilization
100%
Colony Stimulating Factor
100%
Hematopoietic Cell
100%
Apheresis
37%
Autologous Stem Cell Transplantation
25%
Pharmacokinetics
25%
Non-Hodgkin Lymphoma
12%
Multiple Myeloma
12%
Patient Population
12%
Volunteer
12%
Stromal Cell Derived Factor 1
12%
Chemokine Receptor CXCR4
12%
Factor X
12%
Population Dynamics
12%
Immunology and Microbiology
Hematopoietic Cell
100%
Plerixafor
100%
Colony Stimulating Factor
100%
CD34
62%
Apheresis
37%
Autologous Stem Cell Transplantation
25%
Pharmacokinetics
25%
Normal Human
12%
Multiple Myeloma
12%
Chemokine Receptor CXCR4
12%
Stromal Cell-Derived Factor 1
12%
Population Dynamics
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Plerixafor
100%
Colony Stimulating Factor
100%
Pharmacokinetics
25%
Multiple Myeloma
12%
Nonhodgkin Lymphoma
12%
Normal Human
12%
Stromal Cell Derived Factor 1
12%
Blood Clotting Factor 10
12%
Chemokine Receptor CXCR4
12%